August 14, 2024MoleculesOpen Access

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

View Full Paper

Ask AI

Bookmark

Novel quinazoline derivatives exhibit potent antagonist activity at human A2A adenosine receptors, achieving improved solubility alongside nanomolar target affinity.
A high binding affinity Ki of 5 nM was achieved by lead compound 5m, which effectively blocked receptor signaling with an IC50 of 6 µM in a cyclic amp assay.
Supports future therapeutic development of quinazoline derivatives with tertiary amines for cancer and neurodegenerative diseases—in vitro assays; further preclinical work needed.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical testing reveals potent A2A adenosine receptor inhibition by novel quinazoline derivatives, highlighting potential therapeutics for neurodegenerative disorders.

Cite This Study

Laversin et al. (2024) studied this question.

synapsesocial.com/papers/68e5c62db6db64358755d15a https://doi.org/10.3390/molecules29163847

View Full Paper

Ask AI

Bookmark

Implication

Preclinical testing reveals potent A2A adenosine receptor inhibition by novel quinazoline derivatives, highlighting potential therapeutics for neurodegenerative disorders.

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Key Points

Discussion

Implication

Cite This Study

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider